Hematopoietic differentiation of human embryonic stem cells progresses through sequential hematoendothelial, primitive, and definitive stages resembling human yolk sac development by Zambidis, E T et al.
  
 
 
 
Edinburgh Research Explorer 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Hematopoietic differentiation of human embryonic stem cells
progresses through sequential hematoendothelial, primitive, and
definitive stages resembling human yolk sac development
Citation for published version:
Zambidis, ET, Peault, B, Park, TS, Bunz, F & Civin, CI 2005, 'Hematopoietic differentiation of human
embryonic stem cells progresses through sequential hematoendothelial, primitive, and definitive stages
resembling human yolk sac development' Blood, vol. 106, no. 3, pp. 860-870. DOI: 10.1182/blood-2004-11-
4522
Digital Object Identifier (DOI):
10.1182/blood-2004-11-4522
Link:
Link to publication record in Edinburgh Research Explorer
Document Version:
Publisher's PDF, also known as Version of record
Published In:
Blood
Publisher Rights Statement:
Copyright © 2005, The American Society of Hematology
General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s)
and / or other copyright owners and it is a condition of accessing these publications that users recognise and
abide by the legal requirements associated with these rights.
Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer
content complies with UK legislation. If you believe that the public display of this file breaches copyright please
contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and
investigate your claim.
Download date: 05. Apr. 2019
HEMATOPOIESIS
Hematopoietic differentiation of human embryonic stem cells progresses through
sequential hematoendothelial, primitive, and definitive stages resembling human
yolk sac development
Elias T. Zambidis, Bruno Peault, Tea Soon Park, Fred Bunz, and Curt I. Civin
We elucidate the cellular and molecular
kinetics of the stepwise differentiation of
human embryonic stem cells (hESCs) to
primitive and definitive erythromyelopoi-
esis from human embryoid bodies (hEBs)
in serum-free clonogenic assays. Hemato-
poiesis initiates from CD45 hEB cells with
emergence of semiadherent mesodermal-
hematoendothelial (MHE) colonies that
can generate endothelium and form orga-
nized, yolk sac–like structures that sec-
ondarily generate multipotent primitive
hematopoietic stem progenitor cells
(HSPCs), erythroblasts, and CD13CD45
macrophages. A first wave of hematopoi-
esis follows MHE colony emergence and
is predominated by primitive erythropoi-
esis characterized by a brilliant red hemo-
globinization, CD71/CD325a (glycophorin
A) expression, and exclusively embryonic/
fetal hemoglobin expression. A second
wave of definitive-type erythroid burst-
forming units (BFU-e’s), erythroid colony-
forming units (CFU-e’s), granulocyte-
macrophage colony-forming cells (GM-
CFCs), and multilineage CFCs follows
next from hEB progenitors. These stages
of hematopoiesis proceed spontaneously
from hEB-derived cells without require-
ment for supplemental growth factors dur-
ing hEB differentiation. Gene expression
analysis of differentiating hEBs revealed
that initiation of hematopoiesis corre-
lated with increased levels of SCL/TAL1,
GATA1, GATA2, CD34, CD31, and the ho-
meobox gene-regulating factor CDX4
These data indicate that hematopoietic
differentiation of hESCs models the earli-
est events of embryonic and definitive
hematopoiesis in a manner resembling
human yolk sac development, thus provid-
ing a valuable tool for dissecting the
earliest events in human HSPC genesis.
(Blood. 2005;106:860-870)
© 2005 by The American Society of Hematology
Introduction
Classic and contemporary anatomic studies of human embryos
have revealed that human hematopoiesis begins in the second to
third embryonic weeks with formation of mesoderm-derived blood
islands in the extraembryonic mesoderm of the developing second-
ary yolk sac.1,2 Blood islands develop foci of nucleated erythro-
blasts (“megaloblasts”),3 intimately associated with and sur-
rounded by endothelium. Yolk sac (primitive) blood cells consist of
nucleated primitive erythrocytes expressing exclusively embryonic
hemoglobins (eg, 22 globin chains) and primitive macrophages
that arise without detectable monocytic precursors. Following the
onset of circulation at about 21 days of development, yolk sac cells
are found in embryonic blood. The fetal liver subsequently replaces
the yolk sac as the main hematopoietic organ4,5 with appearance of
definitive enucleate, macrocytic erythrocytes expressing fetal hemo-
globins (eg, 22 globin chains). Definitive blood cells and
hematopoietic stem progenitor cells (HSPCs) can be detected in the
fetal liver and embryo beginning at 5 to 6 weeks but have also been
assayed as early as 4 to 5 weeks from human yolk sac, suggesting a
gradual yolk sac/fetal liver HSPC transition.1,6 The human adult
long-term repopulating HSPC that ultimately seeds the fetal bone
marrow and thymus is the legacy of fetal liver hematopoiesis.
Both yolk sac–derived and aorta-gonad-mesonephros (AGM)–
derived HSPC genesis models have been proposed in murine
systems.7-17 Interestingly, in both mouse and humans, there is
compelling evidence that both yolk sac– and AGM-derived HSPCs
are the direct progeny of a bipotential hemogenic endothelial cell or
hemangioblast.18-24
In contrast to zebrafish and mouse, the early developmental
biology of human HSPCs remains difficult to approach due to
ethical and technical limitations of studying human embryos. In
light of fundamental differences between rodent and human
developmental hematopoiesis, including anatomically more
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complex primary and secondary yolk sacs, a relatively shortened
yolk sac phase,25 and a much earlier onset of medullary hematopoi-
esis26 in humans, direct extrapolation of murine development to
humans may be inappropriate. Furthermore, although studies with
scarce human embryo tissues have provided limited insight into the
emergence of HSPCs within the 3- to 5-week human embryo,23-24 it
remains impossible to study the initial commitment of mesoderm to
angiohematopoiesis because human yolk sac blood islands develop
as early as 16 to 17 days of development.
Pluripotent mouse embryonic stem cells (mESCs) have demon-
strated capacity to differentiate into hematoendothelial progenitors
in a manner recapitulating in vivo murine embryonic hematopoi-
esis.27-31 In vitro differentiation of human embryonic stem cells
(hESCs)32,33 similarly provides opportunities to elucidate the
origins of human hematopoiesis. Recent studies have demonstrated
that hESCs can differentiate to hematopoietic colony-forming cells
(CFCs) using either stromal coculture or human embryoid body
(hEB)–based systems.34-37 However, whereas primitive and defini-
tive hematopoiesis have been documented in mESC models,27-31
sequential and spontaneous waves of primitive and definitive
hematopoiesis38-44 have not been delineated from hESCs. This
obstacle limits interpretation and usefulness of hESCs as tools for
dissecting the earliest cellular/molecular events in human embry-
onic hematopoiesis, including the search for a clonogenic human
hemangioblast. Additionally, unlike mouse ES/EB systems, proto-
cols for efficient commitment to hematopoietic cells thus far appear
to require pretreatment of differentiating hEBs with complex cocktails
of growth factors that induce, augment, but also likely skew spontane-
ous hematopoietic commitment of hEB progenitors.34,35
The derivation of genetically modified45,46 hematoendothelial
progenitors from hESCs may provide a versatile source of both
HSPCs and endothelial cells for human tissue engineering. More
importantly, the basic cellular and genetic mechanisms of human
hematopoietic incipience can now be opened to thorough investigation.
Materials and methods
Culture of hESC and hEB differentiation
The hESC line H1 (National Institutes of Health [NIH] code: WA01) was
maintained on irradiated primary murine (CF1) primary murine embryonic
fibroblasts (PMEFs) as previously described32,33 and maintained a continu-
ously pluripotent phenotype (more than 80% to 90% GCTM2CD9,
SSEA4, SSEA1, OCT4, and alkaline phosphatase positive 32,33). Freshly
thawed hESCs (fewer than 45 passages) with confirmed normal male
karyotypes were used for all differentiation experiments. Feeder-free
culture on Matrigel prior to hEB formation was avoided.
Our methods for hEB differentiation (Figure S1A, available on the Blood
website; see the Supplemental Figures link at the top of the online article) were
modified from previous approaches for forming mouse EBs (mEBs) in semisolid
and liquid medium.27,31,47 hESC/PMEF cocultures in 6-well gelatinized plates
were grown to about 80% confluence. Twenty-four hours prior to hEB formation,
serum-free hESC medium was switched to “adaptation medium” consisting of
Iscove modified Dulbecco medium (IMDM) containing 20% ES-certified,
heat-inactivated fetal calf serum (FCS) (HyClone, Logan, UT), 1 mM glutamine,
0.1 mM 2-mercaptoethanol (2-ME), minimum essential medium (MEM) nones-
sential amino acids, and 4 ng/mL basic fibroblast growth factor (bFGF)
(Invitrogen, Carlsbad, CA). IMDM/FCS-adapted hESC cultures were harvested
with 2 mg/mL dispase. hESC clumps were washed and recultured at high density
(contents of 2 wells of confluent hESCs into 1 well for hEB culture) in 6-well
ultra nonadherent plates (Corning, Corning, NY) in 3 to 4 mL IMDM-based 1%
methylcellulose medium (SF H4236; StemCell Technologies, Vancouver, BC,
Canada) supplemented with 15% FCS (StemCell Technologies), 50 g/mL
ascorbic acid (Sigma, St Louis, MO), 0.5% cholesterol/lipoprotein supplements
(EX-CYTE; Serologicals, Norcross, GA), and 3.5% protein-free hybridoma
medium-II PFHM-II (Invitrogen). Semisolid hEB cultures were harvested after 4
days, washed, and resuspended in conical tubes in 50 mL phosphate-buffered
saline (PBS). Formed hEBs were collected by gravity settling for 3 to 5 minutes,
followed by aspirating the upper two thirds of the hEB suspension. This step
efficiently eliminated more than 90% of nonviable, irradiated PMEFs. Formed
hEBs were replated (about 300 to 500/mL) in ultra nonadherent 6-well plates in 4
mL “liquid differentiation medium” consisting of serum-free expansion medium
(SFEM) (StemCell Technologies) supplemented with 15% FCS, 50 g/mL
ascorbic acid, 0.5% EX-CYTE, 0.5% insulin/transferrin/selenium supplements
(Invitrogen), 5% PFHM-II, and penicillin/streptomycin. hEB liquid cultures were
fed every 3 to 4 days with 2 to 3 mL fresh liquid differentiation medium (or
passaged at a 1:2 ratio).
Replating assays for hematopoietic colony-forming cell (CFC)
or endothelial potential
hEBs were harvested at various time points, washed in PBS, and assayed for
clonogenic hematopoietic progenitors. Single-cell suspensions of hEBs
were made using 0.05% trypsin/EDTA (ethylenediaminetetraacetic acid)
(day 3 to 9 hEBs) or Liberase (Roche, Indianapolis, IN) plus 0.05%
trypsin/EDTA (day 10 to 30 hEBs). Enzymatically loosened hEBs were
passed gently through a 21-gauge needle and triturated into a single-cell
suspension. Viable hEB cells were enumerated, plated (1.0 105 to 1.5  105/
mL), and assayed in humidified chambers for hematopoietic CFCs in 2 mL
serum-free methylcellulose-based medium (H4436; StemCell Technologies)
containing stem cell factor (SCF) 50 ng/mL, erythropoietin (EPO) 3 U/mL,
granulocyte-macrophage colony-stimulating factor (GM-CSF) 50 ng/mL, G-
CSF 50 ng/mL, interleukin-3 (IL-3) 20 ng/mL, and IL-6 20 ng/mL supplemented
with 0.5% EX-CYTE and 5% PFHM-II. Fourteen to 21 days later, colonies were
scored and picked for cytospin or real-time quantitative reverse transcriptase–
polymerase chain reaction (qRT-PCR) analysis.
Erythroid burst-forming units (BFU-e’s) were defined for both primitive
and definitive colonies by standard definitions (3 or more multiclustered
erythroid colonies). Positive control definitive BFU-e’s for intracellular
hemoglobin fluorescence-activated cell sorter (FACS) analyses were gener-
ated by plating CD34 cord blood cells in H4436 medium.
Plastic-adherent cells from individual mesodermal-hematoendothelial (MHE)
colonies were secondarily replated for endothelial differentiation by vigorous
washing away of nonadherent cells, trypsinization, passage through a 21-gauge
needle, and reculture into EGM2 complete endothelial medium (Cambrex
Bioscience, Walkersville, MD) on Matrigel-coated plates. Rapidly prolifer-
ating cells appeared 4 to 7 days after replating and were analyzed for endothelial
function by overnight incubation with 10 g/mL acetylated Dil-LDL (Molecu-
lar Probes, Eugene, OR) or harvested for RNA for RT-PCR analysis.
Flow cytometry analysis of surface markers and hemoglobins
and in situ immunofluorescence
Hematoendothelial markers were evaluated from enzymatically dissociated
hEB cells or individually picked and pooled hematopoietic colonies at
different time points. Fluorochrome-conjugated monoclonal antibodies
included CD31-phycoerythrin (PE), CD34-PE, CD45-PE, CD71–phyco-
erythrin-cyanin 5 (PeCy5), CD13-PE, glycophorin A (CD235A, GlyA)–PE,
vascular endothelial (VE)–cadherin (all from Becton Dickinson, San Diego,
CA), antivimentin (Lab Vision, Fremont, CA), and Ulex europaeus
agglutinin-1–fluorescein isothiocyanate (UEA1-FITC) (Vector Laborato-
ries, Burlingame, CA). Viable cells were gated for analysis and appropriate
isotype and secondary antibody controls compared for each sample using a
FACSort flow cytometer and CellQuest software (Becton Dickinson Immunocy-
tometry Systems [BDIS], San Jose, CA). Hemoglobin F (HbF), hemoglobin A
(HbA), gamma chain, and epsilon chain expression was evaluated by intracellu-
lar FACS staining of fixed, permeabilized colony cells (FIX and PERM; Caltag,
Burlingame, CA) using fluorochrome-conjugated monoclonal antibodies HbF-PE
(Caltag), HbA (beta 6-glu epitope [Cortex, San Leandro, CA] plus secondary
PE-conjugated antibody [Southern Biotech, Birmingham,AL]), gamma chain–PE
(Cortex), and epsilon chain–FITC (Cortex).
Adherent cells of MHE colony cells from CFC assay plates were
analyzed by FACS following dissociation with nonenzymatic cell dissocia-
tion buffer (Invitrogen) and gentle passage through a 21-gauge needle.
Plastic-adherent cells were also analyzed in situ for endothelial function by
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overnight incubation with 10 g/mL acetylated Dil-LDL, followed by fixation/
permeabilization (FIX and PERM; Caltag) and immunostaining with FITC- or
AlexaFluor594-conjugated primary/secondary antibodies/reagents. Nucleii
were counterstained with DAPI (4,6 diamidino-2-phenylindole). All images
were acquired with a Nikon TE200 microscope equipped with a DXM1200F
digital camera and ACTI software (Nikon).
Hematologic stains
Colonies were picked individually from methylcellulose cultures, washed
in PBS/2% FCS, and spun onto poly-D-lysine–coated slides with a cytospin
apparatus (Shandon; Theims, Waltham, MA). Cells were fixed and stained
with Wright-Giemsa reagents (Hema 3 stain; Fisher Scientific, Hampton,
NH). Benzidine-hemoglobin and Kleihauer-Betke (K-B) fetal hemoglobin
stains with erythrosin-B were done on cytospun cells as described.48
qRT-PCR analysis of hEB cells and hematopoietic colonies
To derive baseline hESC mRNA for hEB qRT-PCR studies, viable,
undifferentiated hESCs were purified by FACS (FACSVantage; BDIS) to
more than 95% homogeneity from PMEFs after trypsinization of hESC
cultures and staining with GCTM2 49 supernatant (a kind gift from Martin
Pera) plus anti–mouse immunoglobulin M (IgM)–FITC secondary (Becton
Dickinson), and CD9-PE (Becton Dickinson). GCTM2CD9 cells repre-
sented 80% to 90% of hESCs in healthy, log-phase cultures.
Total RNA from GCTM2CD9-sorted (more than 95% purity) H1
hESCs, hEB cells, or picked, pooled colonies from methylcellulose CFC
medium was prepared using RNEasy reagents (Qiagen, Valencia, CA).
RNA samples were treated with RNAse-free DNAse (Qiagen). First-strand
cDNA was reversed transcribed with oligo-dT priming using Superscript
reagents (Invitrogen). qRT-PCR was performed using iQ SYBR-Green
Supermix reagents and an iCycler thermal cycler and software (Bio-Rad,
Hercules, CA). Human gene–specific PCR amplicons of 90 to 300 bp
(Table 1) were designed with PRIMER 3.0 software for comparison with
human/mouse cDNA GenBank data using basic local alignment sequence
tool (BLAST) (National Center for Biotechnology Information [NCBI])
software. All primers were tested and optimized for specificity and mouse
nonreactivity with SYBR-Green reagents using reverse-transcribed cDNA
from PMEF RNA (negative control), human umbilical vein endothelial cell
RNA (positive control), or human CD34 cord blood RNA (positive
controls). Transcripts of target genes and actin controls for each cDNA
sample were amplified in duplicate/triplicates. All qRT-PCR reactions were
confirmed for specificity of a single PCR product by analysis on 4% agarose
gels. Comparative quantification of each target gene was performed based
on cycle threshold (CT) normalized to actin using the 		CT method.51 The
relative expression of each normalized target gene was compared with the
actin-normalized expression of the target gene (	CT) in highly purified
(GCTM2CD9-sorted) undifferentiated hESCs. “Fold change expression
from undifferentiated hESCs” was calculated as 2		CT, where 		CT 

(	CT hEB cells)  (	CT purified, undifferentiated hESCs). For evaluation
of relative expression levels of target genes in individually picked
hematopoietic colonies, expression was compared with transcript levels of
hEB cells obtained prior to plating in methylcellulose and growth factors.
“Fold change in expression from undifferentiated hEB cells” was similarly
calculated using actin-normalized methods (	CT) and based on the
following equation: 2		CT, where 		CT 
 (	CT colony-forming cells
derived from hEB progenitors)  (	CT preplated total hEB cells).
Results
hESCs efficiently differentiate into cystic hEBs containing
precursors expressing a developmental progression of
hematoendothelial surface markers and regulatory genes
Using modified mEB protocols27,31 (Figure S1A), we differentiated
hESCs into hEBs capable of spontaneously generating hematopoi-
etic progenitors without need for recombinant hematopoietic
growth factors during hEB differentiation.34,35 About 50% to 60%
Table 1. Sequences of human-specific primers used for qRT-PCR
Human-specific genes Forward primer, 53 3 Reverse primer, 53 3
Amplicon size,
base pairs
Annealing
temperature, °C
Actin gca cag agc ctc gcc ttt gga atc ctt ctg acc cat gc 213 59-65
OCT4 gca gct cgg aag gca gat tgg att tta aaa ggc aga aga ctt g 135 63
CD31 gag tcc tgc tga ccc ttc tg att ttg cac cgt cca gtc c 107 61
CD34 tgg acc gcg ctt tgc t ccc tgg gta ggt aac tct ggg 100 61
CD45 cat ttg gct ttg cct ttc tg ttc tct ttc aaa ggt gct tgc 167 61
KDR/flk-1 cca gcc aag ctg tct cag t ctg cat gtc agg ttg caa ag 272 61
Flt-1 gac tag ata gcg tca cca gca g gaa acc gtc aga atc ctc ctc 101 65
VWF ccc gaa agg cca ggt gta agc aag ctt ccg ggg act 288 61-63
VE-cadherin gca gca gca ggt gct aac c ttg ccc aca tat tct cct ttg 203 61
SCL/TAL1 atg aga tgg aga tta ctg atg gcc ccg ttc aca ttc tgc t 100 61
LMO2 aac tgg gcc gga agc tct ctt gaa aca ttc cag gtg ata ca 143 65
EKLF cgg aca cac agg atg act tc ggc tgg tcc tca gac ttc ac 115 59-60
PU.1 cac agc gag ttc gag agc tt gat ggg tac tgg agg cac at 194 61
GATA1 ggg atc aca ctg agc ttg c acc cct gat tct ggt gtg g 176 64-65
GATA2 gcg tct cca gcc tca tct t gga aga gtc cgc tgc tgt ag 226 61
c-myb gtc aca aat tga ctg tta caa cac cat ttc tac tag atg aga ggg tgt ctg agg 212 61
CDX4 ctg tgg gcg gtg gaa cta aaa cta cac gbvat act ttt ctt ttg tcc 186 61
(HOXB4)* gca cgg taa acc cca att a ggc aac ttg tgg tct ttt tt 220 61-65
AML1a† aag aca cag cac cct gga ga gcc ttc ctc ata acg tgc at 151 60
AML1a/b‡ cgt gca cat aca tta gta gca ct acct ttg ctt cca cga atc ttg ctt gca gag gtt aag 304 60
AML1c§ gaa gtc tga acc cag cat agt ggt cag cag gtg gac gtc tct aga agg att cat tcc aag 231 60
Epsilon tgc tat taa aaa cat gga caa cc gcc aga ata atc acc atc acg 126 61
Zeta att gtc tcc atg tgg gcc tct gcg ggt ggc tga g 90 61-63
Alpha aag gtc ggc gcg cac gct ctc agg tcg aac tgc ggg 101 61
Gamma gga caa ggc tac tat cac aag c gga agt cag cac ctt ctt gc 193 63
Beta ggc acc ttt gcc aca ctg cac tgg tgg ggt gaa ttc tt 132 61-63
*These primers do not distinguish between human and murine HOXB4.
†These primers amplify an amplicon in exon 7A of the AML1 gene that is specific for the a isoform of AML1.50
‡These primers amplify an amplicon in exon 3 of the AML1 gene that is specific for both the a and b isoforms of AML1.50
§These primers amplify an amplicon that spans exon 1 and 2 of the AML1 gene and is specific for the c isoform of AML1.50
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of hESC clumps plated became hEBs and acquired a cystic
morphology by 8 to 15 days of differentiation (Figure S1B).
Differentiating hEB cells rapidly decreased expression of OCT3/4
(POU5F1; Figure S1C) and lost markers characteristic of undiffer-
entiated hESCs32,33,49 (GCTM2, CD9, and TRA-1-60, data not
shown) after 3 to 12 days.
To identify when differentiating hEB cells become competent
for generating hematopoietic progenitors, we analyzed hEBs over a
4-week time course for expression of well-characterized hematoen-
dothelial markers using FACS and qRT-PCR. Undifferentiated (day
0) hESCs expressed CD117 (FACS data not shown), CD133
(FACS data not shown), and KDR/flk1 (Figure 1A) but had
low/undetectable expression of CD34 and CD31 RNA or surface
protein (Figure 1A,C). CD34 and CD31 expression both peaked at
about 12 to 15 days of hEB development (Figure 1A,C) and were
coexpressed on the same hEB progenitors (Figure S2B). CD45
(Figure 1A,C) was expressed on only 1% to 3% of hEB cells and
not until about 15 to 30 days (about 1 week after the onset of
CD34/CD31 expression).
hEB cells were next evaluated for hematopoietic gene expres-
sion by qRT-PCR. A kinetic analysis revealed a progressive
expression pattern of genes known (from murine studies) to initiate
and regulate hematopoiesis (Figure 1B). Expression of key hemato-
poietic transcriptional regulators, including SCL/TAL1, CDX4,
GATA1, GATA2, EKLF, and PU.1 were all found to increase
dramatically after 1 week of hEB differentiation (Figure 1B).
Increases in mRNA levels of these transcription factors coincided
with similarly increasing expression levels of CD31, CD34, and
KDR/flk-1 (Figure 1A). Interestingly, several genes important for
regulating HSPC development in MESCs and embryos (eg, LMO2,
AML1, C-MYB [data not shown], KDR/flk-1 [VEGFR2], and FLT-1
[VEGFR1]) were expressed abundantly at the mRNA level in
undifferentiated hESCs as well as in hEBs at all time points (Figure
1A). Although we have not confirmed that mRNA levels correlate
directly with protein levels for these genes, these data suggest
potentially major differences between mouse and human embry-
onic regulation of hematopoiesis. Expression of KDR/flk-1
(VEGFR2, a receptor for vascular endothelial growth factor),
associated with development of hemangioblasts, was only moder-
ately increased but was relatively high at all time points. This is
distinct from mEB differentiation, where a more dramatic expres-
sion profile has been described.52-55 Expression levels for these
genes peaked at days 6 to 10 of hEB differentiation, suggesting a
putative coordinated developmental watershed event in hEB hema-
toendothelial commitment.
Day 7 to 12 hEB cells generate organized, mesodermal-
hematoendothelial (MHE) colonies and a robust wave of
primitive hematopoiesis correlating with increased
expressions of SCL/TAL1, GATA1, GATA2, and CDX4
We reproducibly generated colonies of CFC-mixed, M-CFCs,
GM-CFCs, and erythroid colony-forming units (CFU-e’s) (with
morphologies similar to definitive colonies produced from cord
blood CD34 cells) from day 14 to 20 hEBs using standard
methylcellulose preparations containing FCS, as has already been
reported.34,35 hEB single-cell suspensions obtained at earlier time
points, however, when peak expression levels for key regulatory
genes were observed (days 6 to 12; Figure 1A-B), failed to generate
CFCs using standard methylcellulose media. Because many batches
of bovine serum have been reported to inhibit the expansion of
primitive murine progenitors,27,31,47 we optimized our hEB CFC
assays in serum-free semisolid medium. These conditions revealed
vigorous primitive hematopoietic CFCs starting at 7 to 9 days of
hEB development, beginning with the detection of unique, laterally
expanding semiadherent MHE colonies (Figure 2A-B). CFC
generation was not detectable from hEB cells differentiated for
fewer than 7 days. MHE colonies expanded either as clonogenic
adherent clusters (Figure 2A) or, rarely, from differentiating
plastic-adherent secondary hEBs. Early MHE colonies are first
detected as adherent clusters of cells with an endothelioid morphol-
ogy (Figure 2D, left 2 panels) about 1 week after single hEB cell
plating, followed by a rapid secondary budding/differentiation of
hematopoietic blast colonies several days later (Figures 2A and
3A-B,G). The cellular architecture (Figure 2A) of many MHE
cluster colonies differentiated for 2 to 5 weeks was highly
reminiscent of human yolk sac blood islands.3
Adherent and nonadherent cells of MHE colonies derived from
day 7 to 12 hEBs differentiated fully for more than 2 to 4 weeks in
methylcellulose with growth factors were picked and analyzed
separately by FACS and in situ immunofluorescence. Adherent
cells of mature MHE colonies (obtained after vigorous washing of
nonadherent cells) took up acetylated Dil-LDL (Figure 3F) and
expressed CD31 (more than 50%; Figure 3G) and VE-cadherin
(11%; data not shown), but not CD45 (not shown), while budding,
loosely associated cells expressed erythromyeloid markers CD71,
Figure 1. Quantitative real-time RT-PCR and FACS expression analysis of key
hematoendothelial genes in differentiating hEBs. Human-specific PCR primers
(Table 1) were used to amplify indicated target genes. Levels of gene expression
differences for (A) hematoendothelial surface markers or (B) hematopoietic regula-
tory transcription factors were calculated using the 2		CT method as described in
“Materials and methods,” based on the CT (threshold curve) for each target gene and
internal normalizations with actin. Values of fold change in expression are relative to
baseline expression levels in FACS-sorted populations of undifferentiated hESCs
(day 0 hEBs) and are expressed as “fold expression from undifferentiated hESC.”
Shown above graphs are the corresponding agarose gels of PCR products obtained
at linear phases of qPCR reactions. Standard deviations between duplicate or
triplicate samples are shown. PECAM indicates platelet-endothelial cell adhesion
molecule 1. (C) Developmental progression of hematoendothelial surface marker
expression on disaggregated hEB cells at various time points. “% positive hEB cell”
represents fluorescence value obtained by FACS analysis following subtraction of
control sample background. Each time point represents the mean of 3 to 5
independent experiments with indicated standard deviations.
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CD13, and CD45 (Figure 2C). Wright stains of nonadherent cells
(Figure 2A, lower left panel) revealed primitive-type foamy
macrophages (without evidence of monocytic precursors) and
abundant nucleated, primitive-type erythroblasts. Rare definitive
granulocytes were also detected (not shown). Interestingly, endothe-
lial characteristics such as Dil-LDL uptake and VE-cadherin
expression were present in early (about 1 week after hEB cell
plating; Figure 2D, first left panel) adherent MHE colonies, prior to
hematopoietic differentiation/budding.
The bed of plastic-adherent cells of more mature (about 3 to 5
weeks after plating) MHE colonies was analyzed in situ in more
detail following vigorous washing away of nonadherent cells.
Overnight incubation of adherent cells with acetylated Dil-LDL
and subsequent incubation with endothelial-specific Ulex euro-
paeus agglutinin-1–FITC (UEA1-FITC) revealed that about 20%
of cells costained with these markers (Figure 2D; FACS analysis of
dissociated adherent cells, Figure 2E). Interestingly, these studies
revealed that a significant portion of adherent cells of MHE
colonies did not stain for any endothelial-specific markers (com-
pare phase with fluorescent images; Figure 2D). These cells,
however, stained abundantly for the mesenchymal marker vimentin
(Figure 2D, right 4 panels), thus demonstrating that endothelial
cells were intermixed with cells of nonendothelial, mesodermal
origin. This important result suggests that MHE colonies likely
arise from hEB-derived mesodermal progenitors capable of giving
rise to primitive-type erythromyeloid cells, endothelial cells, and
mesenchymal stromal cells: the 3 essential cellular components of
yolk sac blood islands.
To further characterize these complex MHE colonies, we
conducted secondary replating assays of adherent and nonadherent
portions of early (about 1 week after replating), developing MHE
colonies. Our hypothesis was that the mesodermal progenitor(s),
which generates MHE colonies, can secondarily give rise to
clonogenic progenitors of either hematopoietic (nonadherent) or
endothelial (adherent) lineages. Individual budding hematopoietic
blast colonies (Figure 3B) from early MHE colonies (Figure 3A,G)
containing few differentiating, hemoglobinizing cells were care-
fully picked. These colonies were dissociated into single cells and
replated for secondary colony analysis (Figure 3D-E). Most (more
than 70%) MHE colony-derived hematopoietic blast colonies
generated new colonies in methylcellulose with growth factors and
readily produced secondary primitive-type mixed erythromyeloid,
pure erythroid, or pure macrophage colonies (Figure 3E). This
demonstrated that MHE colonies generate multipotent hematopoi-
etic progenitors. In parallel experiments, the adherent cells of
individual MHE colonies, which were about 50% to 60% CD31
(Figure 3G) and CD45 (not shown), were enzymatically dissoci-
ated into single cells and recultured in EGM2 medium with
endothelial growth factors. Adherent cells from 6 of 6 (100%)
individual MHE colonies rapidly grew cells of endothelial morphol-
ogy, had ability to take up acetylated Dil-LDL, and expressed
endothelial genes including von Willebrand factor (VWF) and
VE-cadherin but not the hematopoietic marker gene CD45
(Figure 3G).
Colonies with a primitive erythroblast morphology expanded in
semisolid medium with growth factors from day 7 to 12 hEB cells
in the absence of any obvious MHE source. Primitive erythroblast
colonies differentiated into either large primitive multiclustered
erythroid colonies (Figure 4A, BFU-e-P) or, less commonly, mixed
erythromyeloid colonies (Figure 5C; MIXED-P). These erythro-
blasts produced distinctive brilliant red hemoglobinized, nucleated
erythroid colonies (Figure 4A, EryP or BFU-e-P). Macrophage
Figure 2. Hematopoietic differentiation from recultured hEB cells initiates with expansion of adherent MHE colonies. Single-cell suspensions of hEB cells
differentiated for 3 to 25 days were plated in modified serum-free methylcellulose medium containing hematopoietic growth factors as described in “Materials and methods.”
(A) Within 1 to 3 weeks following day 7 to 12 hEB cell suspension CFC assay plating, a population of semiadherent MHE colonies expanded either from plastic-adherent hEB
clonogenic progenitors, or rarely from attached secondary hEBs. Plastic-adherent MHE colonies (i; magnification  200) differentiate by lateral endothelioid expansion
accompanied by budding, hemoglobinizing hematopoietic blasts (arrows) that are intimately intermixed with adherent cells (ii; magnification  40). MHE clusters can become
quite prolific after 3 to 5 weeks (iii; magnification  200) if refreshed with fresh medium with growth factors every 1 to 2 weeks. Wright stains (iv; magnification  600, oil) of
budding, nonadherent cells from prolific MHE clusters revealed abundant hematopoietic blasts (Bl), primitive nucleated erythrocytes (EryP), foamy primitive macrophages
(Macro-P), and rare definitive cells including granulocytes and definitive erythroid cells (not shown). (B) Kinetics of MHE colony appearance from differentiating hEBs (mean
and standard deviations of 3 independent experiments). Loosely adherent cells from prolific HE clusters were picked and analyzed by FACS (C) and found to express abundant
levels of early erythroid (CD71), myeloid (CD13), and panhematopoietic (CD45) markers. Mature (3- to 5-week-old) MHE colonies were extensively washed of budding,
nonadherent hematopoietic cells, and remaining plastic-adherent cells were incubated with 10 g/mL acetylated Dil-LDL overnight and then fixed, permeabilized, and further
evaluated for expression of endothelial-specific and mesodermal markers. Approximately 15% to 20% of elongated, plastic-adherent cells that formed the base of MHE
colonies were shown by in situ immunofluorescence (D) or FACS analysis (as single cells) (E) to be capable of simultaneously taking up acetylated Dil-LDL and costaining with
either Ulex europaeus agglutinin-1–FITC (D; UEA1, magnification  100) (E) or VE-cadherin plus FITC-conjugated secondary antibody (D; magnification  200). The
remainder of the adherent cells that surrounded intermixed, robust Dil-LDL–positive endothelial clusters stained brightly for intracellular vimentin, thus identifying them as
mesodermal-mesenchymal (nonendothelial) in lineage (D, right 4 panels; magnification 100, 200, respectively). Shown are merged images of phase and red and/or green
immunofluorescent filters.
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colonies with a foamy cytoplasmic morphology (Figure 5D,
Macro-P), and without associated monocytic precursors, were also
abundant at this time and were identical on Wright stains to
macrophages arising from HE clusters (Figure 2A). Primitive
erythroblast colonies were picked at early stages (7 to 10 days after
hEB replating) for benzidine-hemoglobin staining, which demon-
strated the presence of nucleated hemoglobin-containing erythro-
blasts and erythrocytes intermixed with immature blast cells
(Figure 4C). These erythroblasts were determined by K-B stains to
express abundant amounts of fetal hemoglobins (Figure 4C).
Day 7 to 12 hEB cells thus contained primitive hematopoietic
CFCs, which were observed to arise from hEB-derived endothe-
lioid MHE progenitors. These cellular events, indicative of primi-
tive embryonic hematopoiesis, were directly associated with in-
creases of SCL/TAL1, CDX4, GATA1, GATA2, CD31, and CD34 by
more than 10- to 10 000-fold in day 7 to 9 cystic hEBs (Figure 1B).
Although we have not directly proven it, this critical temporal
window may represent a hemangioblastic commitment phase in
differentiating hEBs. Importantly, no CD45 hEB progenitors were
detected by FACS or qRT-PCR (Figure 1A,C) during this time
period, although large numbers of CD45 cells were clearly
produced from day 9 to 12 hEB-derived MHE colonies following
reculture of CD45-hEB cells in semisolid medium with hematopoi-
etic growth factors.
Definitive hematopoietic cells develop from day 12 to 20 hEBs
following primitive erythromyelopoiesis from day 7 to 12 hEBs
Kinetic analysis of hematopoietic CFCs generated from day 3 to 20
hEB cells in serum-free CFC assay conditions revealed a rich
variety of hematopoietic colonies with both primitive and definitive
morphologies. Erythroid colonies observed from day 12 to 20 hEBs
cells differed notably in morphology from those observed from day
7 to 12 hEBs. These latter colonies had definitive BFU-e– and
CFU-e–derived morphologies, with a salmon red (as opposed to
brilliant red) hemoglobinization, similar to erythroid colonies
generated from cord blood progenitors.
To further evaluate erythroid colonies scored morphologically
as primitive or definitive (Figure 4D), colonies were picked,
pooled, and analyzed for hemoglobin expression by qRT-PCR or
intracellular FACS analysis. Erythroid colonies from day 7 to 12
hEBs (Figure 4D, BFU-e-P and EryP) expressed embryonic (22)
and fetal (HbF, 22) but not adult (HbA, 22) hemoglobins
(Figures 4F and 6B,D). The second wave of salmon red–colored
erythroid colonies from day 12 to 20 hEBs scored as definitive
(Figure 4D, BFU-e-D, CFU-e-D), however, could be shown to
express not only embryonic (22) and fetal (HbF) but also adult
(HbA) hemoglobins (Figures 4F and 6B). Thus, day 12 to 20
erythroid colonies are more similar to BFU-e– and CFU-e–derived
colonies generated from neonatal CD34 cord blood cells. Intracy-
toplasmic staining with an anti–gamma-PE hemoglobin chain
antibody gave identical results for all erythroid colonies as staining
with the anti-HbF antibody (data not shown). CD71 and GlyA
coexpression was found to be comparable between primitive and
definitive-type erythroid colonies (Figure 4E).
Two types of mixed-lineage colonies were generated from
dissociated hEB cells in serum-free CFC assay conditions. Blast
colonies from day 7 to 12 hEBs arising either directly from HE
colonies (Figure 4A) or from single hEB cells were observed to
Figure 3. Secondary blast colonies can arise directly from adherent MHE colonies and differentiate directly to primitive erythroblasts, macrophages, or mixed
erythromyeloid colonies. During their initial differentiation, adherent MHE clusters (A; magnification  100) often produced secondary budding, blast colonies (B,
magnification  200) with a Wright-Giemsa stain hematopoeitic blast morphology (C; magnification  1000, oil) and that differentiated rapidly into hemoglobinizing cells. To
further evaluate the clonogenic potential of MHE-derived budding hematopoietic blast colonies derived from day 7 to 9 hEB cells, they were individually picked prior to full
differentiation (about 1 week after hEB plating) and recultured in H4436 supplemented with 50 ng/mL bone morphogenetic protein 4 (BMP4) (which greatly improved their
replating efficiency). Single, picked, MHE-derived primary blast colonies (B) were demonstrated to be multipotential by their ability to give rise to multiple secondary mixed,
macrophage, or erythroid colonies (D,E) in secondary replating experiments ([E] with 5 of 7 primary blast colonies successfully replated in a representative experiment
repeated 3 times). After 4 to 6 weeks of continuous culture, prolific, mature MHE clusters (F, left panel; magnification  40) are composed of nonadherent hematopoietic cells
arising from an adherent bed of mesenchymal-endothelial cells. When nonadherent cells are extensively washed away and adherent cells were incubated overnight with
acetylated Dil-LDL, approximately 20% to 30% of adherent cells were positive (F, right panel). To further evaluate the endothelial component of MHE colonies, adherent cells
from individual colonies (Gi) were picked, disaggregated, analyzed by FACS, or replated in endothelial medium (EGM2) on Matrigel-coated plates. Replated adherent cells
from 6 of 6 individual MHE colonies gave rise to cells with endothelial morphology (ii) and ability to take up acetylated Dil-LDL after several days of EGM2 endothelial culture.
(iv) These cells were further evaluated for expression of endothelial genes including von Willebrand factor (VWF) and VE-cadherin by qRT-PCR (HU indicates human umbilical
vein endothelial cell [HUVEC] RNA control; C, cord blood RNA control; E, endothelial cells from replated MHE adherent layers). More than 50% to 70% of elongated, adherent
cells expressed CD34 and/or CD31 (iii, left); EGM2 replated adherent cells continued to express CD31/CD34 and were devoid of CD45 expression (iii, right).
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differentiate into not only BFU-e-P but also into large, mixed
primitive colonies (mixed CFC-P) containing nucleated primitive
erythroblasts and primitive macrophages (Figure 5A,C). Mixed
CFC-P erythromyeloid colonies expressed exclusively embryonic
and fetal hemoglobins (Figure 6B) and thus appear to be the
progeny of a yolk sac–like hematopoietic progenitor, similar to the
blasts budding from MHE colonies. The second type of mixed
colony had a more definitive erythromyeloid morphology (Figure
5E, MIXED CFC-D) and predominated in CFC cultures from day
12 to 20 hEBs. These colonies contained a mixture of mature
erythroid cells, definitive-type monocyte/macrophages, and rare
segmented neutrophils. Colonies derived from mixed CFC-D,
unlike mixed CFC-P (Figure 5C), were distinguished by a more
compact, colony morphology, salmon red hemoglobinization, and
expression of embryonic/fetal and adult (-globin) hemoglobin
chains (Figure 6B). Also generated from day 12 to 20 hEB cultures
were definitive-type GM-CFC and M-CFC colonies containing
monocytes, macrophages, and rare segmented neutrophils (Figure
5B,F). These definitive myeloid-lineage colonies with abundant
monocytic precursors (Figure 5F) contrasted to the primitive
macrophage colonies (Figure 5B,D, Macro-P CFC) that had a
foamy cytoplasm and no apparent monocytic precursors.
Thus, our assay conditions revealed 2 distinct waves of
hEB-derived hematopoiesis, with predominance of multipotent
primitive hematopoietic CFCs arising from day 7 to 12 hEB cells,
followed by a wave of definitive multipotent CFCs arising from
day 12 to 20 hEB cells.
hEB-derived primitive versus definitive colonies display
distinct molecular phenotypes
To further characterize the various clonogenic cell types generated
from hEBs, we picked and pooled individual colonies with
Figure 4. Day 7 to 20 hEB cells contain clonogenic progenitors for both
primitive and definitive erythropoiesis. Erythroid colonies with a “brilliant red”
hemoglobinization from day 9 hEB-derived BFU-e-P (Ai; magnification  100) and
EryP (ii; magnification  100) containing nucleated primitive erythrocytes were
generated from day 7 to 15 day hEBs. Erythroid colonies containing a brownish,
“salmon-red” hemoglobinization were generated from day 12 to 20 day hEBs ([B]
BFU-e-D, CFU-e-D). Colonies (3 to 5 pooled) were picked from semisolid medium for
staining or FACS analyses. Wright stains from multiclustered BFU-e-P (Aiii; magnifi-
cation  600) revealed an increased abundance of erythroblasts, while more mature
EryP (iv; magnification  600) contained primarily differentiated nucleated erythro-
cytes. Primitive erythroblast (Bl) colonies predominate from day 9 to 12 hEBs
differentiate directly into nucleated erythrocytes positive for hemoglobin by benzidine
staining (C, top; magnification 400). Erythroblast colonies stain brightly positive for
fetal hemoglobins by erythrosin-B K-B stains (C, bottom; magnification  200).
(Inset) Positive control K-B staining from maternal peripheral blood with 10% fetal
erythrocyte cells. (D) Kinetic analysis of primitive and definitive erythroid CFCs.
Shown is a representative analysis of 3 independent experiments. Although all types
of erythroid CFCs had surface expression of CD71/GlyA cells (F) and expressed
various levels fetal hemoglobin (HbF), only day 12 to 20 BFU-e-D and CFU-e-D
expressed adult hemoglobin A (HbA). Day 15 to 20 BFU-e-D or CFU-e-D often
contained brownish, lysed cells. Coexpression of both HbF and HbA in BFU-e-D from
CD34 cord blood (CB) progenitors was used as a positive control ([F] CB BFU-e).
Figure 5. Day 7 to 20 hEB cells contain clonogenic, multilineage erythromyeloid
progenitors for both primitive and definitive hematopoiesis. (A) Kinetics of
mixed, multipotent erythromyeloid primitive (Mixed CFC-P) or definitive (Mixed
CFC-D) colonies. (B) Kinetics of primitive macrophage (Macro-P) colonies and
definitive GM-CFC and M-CFC (scored in combination and presented together as
“GMCFC-D”). Shown is a representative experiment performed 3 independent times.
Large, loosely packed primitive mixed erythromyeloid colonies (C; MIXED-P, magnifi-
cation  100) containing foamy macrophages and primitive erythroblasts (C; Wright
stain, MIXED CFC-P, magnification  600, oil) peak from day 9 to 12 hEBs (along
with primitive erythroid CFCs) and differentiate from blast colonies similar to those
that arise from MHE clusters. (D) Foamy macrophage colonies with no evidence of
monocytic precursors on Wright stains (magnification 1000, oil) also predominated
from day 9 to 15 hEBs. (E) Compact colonies containing definitive monocytes/
granulocytes (MIXED CFC-D) as well as GMCFC-D (F, left and middle; magnification
 1000, oil) and M-CFC-D (F, right; Wright stain, magnification  600, oil) arose
primarily from day 12 to 20 hEBs. (G) Day 9 hEB-derived MIXED CFCs (C) were
picked (2 to 3 colonies) and shown by FACS analysis to express abundant amounts
of CD71 and CD45 (as well as CD13; not shown). Shown in the bottom row is the
FACS profile of day 9 hEB pooled EryP colonies from the same cultures.
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identical morphologies for qRT-PCR analysis and compared their
gene expression levels to that of pre-CFC assay hEB cells.
Colonies characterized and scored as primitive or definitive had
different expression profiles of key hematopoietic regulatory
genes. Colonies derived from primitive erythroid CFCs (BFU-e-P
and EryP) had considerably higher levels of GATA1 and EKLF than
did mixed primitive (mixed-P) or mixed definitive (mixed-D)
colonies, consistent with the critical roles of these genes in
regulating embryonic erythropoiesis (Figure 6A). HOXB4, a ho-
meobox gene associated with self-renewal of HSPCs,56 was
expressed in high amounts preferentially in multilineage mixed
colonies (either primitive and definitive). Interestingly, although
SCL, LMO2, AML1b, and CDX4 were each expressed in abundant
amounts in all types of colonies analyzed, the levels of CDX4 were
highest in mixed-D colonies. In addition, C-MYB and AML1c
(Figure 6A), known for their role in regulating multilineage
definitive hematopoiesis, were expressed in high amounts exclu-
sively in mixed erythromyeloid definitive colonies (which also
expressed adult -globin; Figure 6B).
Discussion
ESC differentiation has been accepted as a valid in vitro model for
murine yolk sac hematopoiesis. Developing mEBs produce yolk
sac–like blood islands27 coinciding with cyst formation in the
EBs.57 We show herein that a similar developmental process
operates in differentiating human EBs, albeit with slower kinetics
than for mEBs.27
Although blood elements have recently been reported from
differentiated hESCs,34,35,37 neither the delineated phases of primi-
tive and definitive hematopoiesis nor a clonogenic human heman-
gioblast (which directly precedes primitive erythropoiesis in mEB
systems) have yet been described. Evidence for a clonogenic
mouse hemangioblast has been provided with characterization of a
bipotential yolk sac–like progenitor termed the “blast colony-
forming cell” (BL-CFC).38,41,43 This transient, VEGF-responsive,
mEB-derived progenitor is believed to arise physiologically from
mesoderm in vertebrate yolk sac and has been shown to be a
common progenitor for primitive erythroblasts as well as definitive
erythromyeloid blood cells.28 In mice, hemangioblasts are likely
contained within a subset of KDR/flk-1 mesoderm cells, and in
developing mEBs41 they can be enriched with this marker.
Our studies have not yet demonstrated a clonogenic bipotential
human hemangioblast. As a first step toward this goal, however, we
have herein described an hEB-based system where both primitive
and definitive human hematopoiesis are generated robustly without
requirement for supplemental growth factors34,35 or xenogeneic
stromal cocultures.37 Using serum-free CFC assay conditions, we
have delineated 2 discrete, sequential waves of hematopoiesis
resembling the primitive and definitive hematopoietic patterns
occurring during human yolk sac development.1-3 This process
initiates with primitive erythropoiesis and can be seen to arise
secondarily from adherent MHE progenitors. A wave of primitive
hematopoiesis arose from day 7 to 12 hEBs, and a distinct second
wave of definitive hematopoiesis subsequently arose from day 12
to 20 hEBs. These observations indirectly suggest the development
of a hematoendothelial stem cell at days 6 to 9 of hEB differentia-
tion that either precedes or is concomitant with the burst of
primitive erythropoiesis. The direct visualization of MHE colony-
derived primitive hematopoietic blasts arising in intimate associa-
tion with adherent CD31VE-cadherin endothelial cells during
this time is consistent with this hypothesis. Also in support of this
hypothesis, the emergence of MHE colonies and primitive ery-
throid colonies coincides with a dramatic increase in expression of
SCL/TAL1, GATA1, GATA2, EKLF, PU.1, C-MYB, and CDX4 in
day 6 to 9 hEB cells (consistent with the known importance of these
genes in the commitment of mesoderm to angiohematopoiesis).
Furthermore, expression of early hematoendothelial surface mark-
ers CD31, CD34, and KDR, which all increased prior to onset of
CD45 expression during day 6 to 12 hEB development, also
accompanies (or probably closely follows) hematoendothelial
transcription factor expression. These events are summarized
schematically in Figure 7.
The ontogeny of our novel MHE colonies and their relationship
to clonal bipotential hemangioblasts or more upstream mesodermal
progenitors currently remains unclear. Because we have observed
Figure 6. Molecular phenotypes of primitive erythroid and primitive/definitive
multipotent colonies by real-time qRT-PCR. Day 9 hEB colonies were scored with
primitive/definitive parameters as described in the text. Primitive erythroid (BFU-e-P,
EryP) colonies, primitive mixed (MIXED-P) colonies, and definitive mixed (MIXED-D)
colonies were pooled (2 to 3 colonies), and RNA was analyzed by qRT-PCR methods
as described in text. “Fold change in expression from undifferentiated hEB cells”
was calculated using the 2/		CT method as described in “Materials and methods,”
based on the CT (threshold curve) for each target gene and internal normaliza-
tions with actin. Expression of target genes was compared with levels in
undifferentiated day 9 hEB cells prior to plating. (A) qRT-PCR analysis of key
regulatory genes in primitive and definitive colonies. (B) qRT-PCR expression
analysis of primitive (epsilon, zeta), fetal (alpha, gamma), and definitive adult
(alpha, beta) hemoglobins. (C) qRT-PCR analysis of AML1 isoforms. (D) Corre-
sponding agarose gels of PCR products obtained at linear phases of qPCR
reactions. RNA from erythroleukemia cell line K562 and cord blood were used as
positive controls for qRT-PCR reactions.
A MODEL FOR HUMAN EMBRYONIC HEMATOPOIESIS 867BLOOD, 1 AUGUST 2005  VOLUME 106, NUMBER 3
these semiadherent clusters to occasionally arise from secondary
hEBs after attaching to the culture dish, we cannot definitively rule
out that some MHE colonies may occasionally arise from oligo-
clonal cellular aggregates in our CFC assay.
We are intrigued, however, by the morphologic similarity of
MHE clusters to Bloom and Bartelmez’ classic histologic descrip-
tions of normal intravascular human yolk sac.3 These studies
described “hematocytoblasts” in precirculatory day 13 to 24 human
yolk sac sections as the primary hematopoietic progenitors for
developing yolk sac blood islands, which arose “by direct transfor-
mation of mesenchymal cells.” Basophilic “hematocytoblast cells
with relatively large nucleoli” (similar to our Wright stains of
budding hematopoietic blasts) were observed to give rise to
primitive nucleated erythrocytes and also “phagocytes” in early
yolk sac (day 13). In the later precirculatory yolk sac (day 24),
these same “hematocytoblasts” gave rise to more definitive erythro-
cytes, megakaryocytes, and granulocytes, thus suggesting a com-
mon origin for both primitive and definitive hematopoiesis, as has
been noted in the mouse precirculatory yolk sac.58 Interestingly,
MHE colonies possess comparable developmental characteristics,
including that (1) hematopoietic progenitors arise in intimate
association with endothelial-mesenchymal cells, (2) the predomi-
nant hematopoietic progeny of both MHE colonies and yolk sac
blood islands are nucleated primitive erythroblasts expressing
embryonic/fetal hemoglobins, and (3) primitive hematopoiesis is
sequentially followed by a wave of definitive erythromyelopoiesis.
Both yolk sac– and AGM-derived hematopoiesis appear to be
intimately involved or directly arise from embryonic endothelial
cells in all vertebrate species studied, including humans,19,20,23 thus
suggesting a common hemangioblast for both locations. A recent
study59 has provided evidence that hematopoiesis from hESCs may
similarly arise from hEB-derived endothelial progenitors with a
CD31KDRVE-cadherin phenotype.22 Our preliminary data
(Figure S2) similarly reveal that day 9 to 10 CD45CD34CD31
hEB cells give rise to (at least) definitive lymphohematopoietic cells.
Our results also provide insight into the role key hematopoietic
genes may play in human embryonic development and introduce
experimental approaches for studying mechanisms involved in
normal and genetically modified hESCs. The highly conserved
basic helix-loop-helix (bHLH) transcription factor SCL/TAL1
(stem cell leukemia protein),60 for example, has been shown in
mice and zebrafish to play a crucial role in patterning of mesoderm
into blood and endothelial lineages by regulating the development
of the hemangioblast.60-66 Although its importance in T-cell leuke-
mia67 is established, the role SCL/TAL1 plays in normal human
developmental hematopoiesis remains obscure.62 Our data revealed
that SCL/TAL1 was the first and most dramatically up-regulated
gene coinciding with emergence of primitive hematopoiesis and
was expressed abundantly in all hematopoietic colonies. In con-
trast, other key regulators of mouse hematopoiesis such as LMO2
(LIM domain only protein 2), a LIM-domain binding protein that
physically forms a heterodimer with SCL/TAL1,68,69 KDR/flk-1,
and acute myeloid leukemia-1 (AML1),70,71 were expressed in
large amounts in undifferentiated hESCs, and throughout hEB
differentiation, without correlation to CFC emergence. Expression
analysis of the 3 isoforms of AML1 further revealed that although
AML1b is widely expressed in all CFCs as well as undifferentiated
hEB cells, only the AML1c isoform was expressed in mixed-
definitive colonies. This result is consistent with the hypothesized
role of AML1c in mouse definitive hematopoiesis.50 Another
important observation was the burst of CDX4 expression accompa-
nying SCL/TAL1 peak expression at day 9 of hEB development,
which in turn coincided with the peak of primitive erythroid CFCs
and subsequent emergence of definitive CFCs. Although CDX4
function in humans is unknown, this homeobox gene-regulating
factor, whose absence results in complete loss of blood commit-
ment in “kugelig” zebrafish mutants,72 may similarly be important
for specifying human hemangioblast differentiation.
In summary, we have described an experimental system for the
direct analysis of human embryonic hematopoietic development
that proceeds in a manner appearing to model human yolk sac
development. The key molecular and cellular events of hematopoi-
etic genesis can be delineated in a manner that was previously
impossible due to inaccessibility of human fetal tissue. Further-
more, the potential expansion and transplantation of hematoendo-
thelial stem cells may provide unprecedented translational opportu-
nities for human tissue engineering.
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Figure 7. Summary of cellular and molecular events during hEB differentiation.
(A) Developmental progression of hematoendothelial gene expression during hEB
differentiation. (B) Correlation of key genes and markers to hEB development of
MHE, primitive (PRIM), and definitive (DEF) hematopoiesis.
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